Cargando…
Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo‐controlled randomized cross‐over clinical trial
Iron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side‐effects, high costs, and the lack of availability in many countries with a high prevalence of hereditary anemias. In this phase III randomized placebo‐controlled trial, w...
Autores principales: | van Vuren, Annelies, Kerkhoffs, Jean Louis, Schols, Saskia, Rijneveld, Anita, Nur, Erfan, Peereboom, Dore, Gandon, Yves, Welsing, Paco, van Wijk, Richard, Schutgens, Roger, van Solinge, Wouter, Marx, Joannes, Leiner, Tim, Biemond, Bart, van Beers, Eduard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325377/ https://www.ncbi.nlm.nih.gov/pubmed/35472008 http://dx.doi.org/10.1002/ajh.26581 |
Ejemplares similares
-
P1566: PROTON PUMP INHIBITION FOR SECONDARY HEMOCHROMATOSIS IN HEREDITARY ANEMIA, A PHASE III PLACEBO-CONTROLLED RANDOMIZED CROSS-OVER CLINICAL TRIAL
por: Van Vuren, A., et al.
Publicado: (2022) -
Liver Iron Retention Estimated from Utilization of Oral and Intravenous Radioiron in Various Anemias and Hemochromatosis in Humans
por: van Vuren, Annelies J., et al.
Publicado: (2020) -
The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance
por: Grootendorst, Simon, et al.
Publicado: (2021) -
P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
por: van Dijk, Myrthe, et al.
Publicado: (2023) -
Iron overload in patients with rare hereditary hemolytic anemia: Evidence‐based suggestion on whom and how to screen
por: van Straaten, Stephanie, et al.
Publicado: (2018)